Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia.

[1]  H. Kantarjian,et al.  Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. , 2005, Blood.

[2]  A. Tefferi,et al.  Clinical correlates of submicroscopic deletions involving the ABL–BCR translocation region in chronic myeloid leukemia , 2005, European journal of haematology.

[3]  W. Sanger,et al.  Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. , 2004, Cancer genetics and cytogenetics.

[4]  A. Green,et al.  Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. , 2003, Blood.

[5]  A. Green,et al.  Survival implications of molecular heterogeneity in variant Philadelphia‐positive chronic myeloid leukaemia , 2003, British journal of haematology.

[6]  M. Rocchi,et al.  Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients , 2002, Genes, chromosomes & cancer.

[7]  L. Trakhtenbrot,et al.  Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. , 2001, Cancer genetics and cytogenetics.

[8]  J. Squire,et al.  Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. , 2001, Blood.

[9]  K. S. Reddy,et al.  A FISH study of variant Philadelphia rearrangements. , 2000, Cancer genetics and cytogenetics.

[10]  M. Leversha,et al.  Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. , 2000, Blood.

[11]  S. Ben-Neriah,et al.  Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. , 1999, Cancer genetics and cytogenetics.

[12]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[13]  P. Koduru,et al.  Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13. , 1993, Oncogene.

[14]  C. Morris,et al.  Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement? , 1991, Cancer genetics and cytogenetics.

[15]  B. Johansson,et al.  Cytogenetic and Molecular Genetic Evolution of Philadelphia-Chromosome-Positive Chronic Myeloid Leukaemia , 2003 .

[16]  L. Campbell,et al.  a powerful and independent prognostic indicator in chronic myeloid leukemia , 2001 .

[17]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .